06:40 AM EST, 11/08/2024 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) reported Q3 adjusted earnings Friday of $0.16 per diluted share, down from $0.19 a year earlier.

Four analysts polled by Capital IQ expected $0.14.

Net revenue for the quarter ended Sept. 30 was $702.5 million, up from $620 million a year earlier.

Three analysts polled by Capital IQ expected $693.7 million.

For 2024, the company continues to expect adjusted EPS of $0.57 to $0.63. Four analysts surveyed by Capital IQ expected $0.60.

Full-year net revenue is projected to be $2.70 billion to $2.80 billion. Three analysts polled by Capital IQ expect $2.75 billion.